Details of the Drug

General Information of Drug (ID: DMF9M57)

Drug Name

Cotellic

Synonyms

Cobimetinib fumarate; Cobimetinib Fumarate; Cobimetinib hemifumarate; Xl-518 hemifumarate; GDC-0973 hemifumarate; UNII-6EXI96H8SV; 6EXI96H8SV; Cobimetinib fumarate [USAN]; 1369665-02-0; Cobimetinib fumarate (USAN); Cotellic (TN); CHEMBL2364607; CHEBI:90853; Methanone, (3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(3-hydroxy-3-(2S)-2-piperidinyl-1-azetidinyl)-, (2E)-2-butenedioate (2:1); D10615; bis[(2S)-2-{1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]-3-hydroxyazetidin-3-yl}piperidin-1-ium] (2E)-but-2-enedioate

Indication

Disease Entry	ICD 11	Status	REF
Melanoma	2C30	Phase 3	[1]
Breast cancer	2C60-2C65	Phase 2	[2]
Head and neck cancer	2D42	Phase 1	[2]
Renal cell carcinoma	2C90	Phase 1	[2]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
Urothelial carcinoma	2C92.0	Phase 1	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C21H21F3IN3O2
Canonical SMILES: C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O
InChI: 1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2/t17-/m0/s1
InChIKey: BSMCAPRUBJMWDF-KRWDZBQOSA-N

Cross-matching ID

PubChem CID: 16222096
ChEBI ID: CHEBI:90851
CAS Number: 934660-93-2
TTD ID: D0FJ9I

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	ClinicalTrials.gov (NCT01106599) A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0623 in Patients With Locally Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health.